A 6 Month Safety Extension Study of MBGS205
A 6 Month, Double-blind Safety Extension Study of MBGS205
Sponsor: Mereo BioPharma
This PHASE2 trial investigates Hypogonadotropic Hypogonadism and is currently completed. Mereo BioPharma leads this study, which shows 15 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jun 2023 [monthly]
Completed PHASE2
▶ Show 10 earlier versions
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Nov 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
-
Aug 2017 — Apr 2018 [monthly]
Enrolling By Invitation PHASE2
-
Jul 2017 — Aug 2017 [monthly]
Enrolling By Invitation PHASE2
-
Jun 2017 — Jul 2017 [monthly]
Enrolling By Invitation PHASE2
-
Apr 2017 — Jun 2017 [monthly]
Enrolling By Invitation PHASE2
-
Feb 2017 — Apr 2017 [monthly]
Enrolling By Invitation PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE2
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mereo BioPharma
For direct contact, visit the study record on ClinicalTrials.gov .